Table 2.
Ongoing clinical trials of gemtuzumab ozogamicin for acute myeloid leukemia
| NCT number | Phase | Conditions | Interventions | Recruitment |
|---|---|---|---|---|
| NCT03727750 | IV | CD33+ R/R AML | Evaluate the QTc, pharmacokinetics, safety of GO | Not yet recruiting |
| NCT03374332 | II | R/R AML | GO (D1, 4, 7) followed by non-engraftment donor leukocyte infusion | Not yet recruiting |
| NCT03737955 | II | AML with MRD | GO (D1, 4, 7) | Recruiting |
| NCT02473146 | II/III | Elderly AML patients | GO (D1, 4) + cytarabine (D1–7) vs idarubicin (D1–3) + cytarabine (D1–7) | Recruiting |
| NCT03672539 | II | R/R AML | GO + CPX-351 (liposome-encapsulated daunorubicin-cytarabine) | Recruiting |
| NCT02221310 | II | High risk CD33+ AML/MDS | GO + busulfan + cyclophosphamide followed by ASCT | Recruiting |
| NCT03839446 | II | AML refractory to initial standard induction | GO + mitoxantrone + etoposide | Recruiting |
| NCT02117297 | II | Average risk AML/MDS | ASCT followed by GO (D3, 56 post transplatation) | Recruiting |
| NCT03848754 | I | R/R AML | GO (D1, 4, 7) + Pracinostat | Recruiting |
| NCT03531918 | I/II | ND AML or high-grade myeloid neoplasm | GO + G-CSF + Cladribine + Cytarabine + Mitoxantrone | Recruiting |
| NCT03900949 | I | ND FLT-3 mutated AML | GO (D1, 4, 7) + DA (3 + 7) + midostaurin (D8–21) | Recruiting |
| NCT00801489 | II | ND AML and high-risk MDS | GO + fludarabine phosphate + cytarabine + filgrastim-sndz + idarubicin hydrochloride | Recruiting |
| NCT03390296 | I/II | R/R AML | GO + azacytidine + venetoclax or avelumab | Recruiting |
| NCT01409161 | II | ND acute promyelocytic leukemia | Tretinoin + Arsenic Trioxide ± GO | Recruiting |
GO Gemtuzumab ozogamicin, ASCT Allogenic stem cell transplantation, DA Daunorubicin + cytarabine, G-CSF Granulocyte colony stimulating factor, MDS Myelodysplastic syndrome, MRD Measurable residual disease, ND Newly diagnosed, R/R Refractory or relapse